Clinical Trials Directory

Trials / Sponsors / CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Industry · 22 registered clinical trials11 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingA Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterol
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Phase 32026-03-31
Not Yet RecruitingA Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 32026-03-31
RecruitingA Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial H
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Phase 32026-02-28
Not Yet RecruitingA Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of S
Healthy Subjects
Phase 12025-11-24
RecruitingA Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of S
Healthy Subjects (HS)
Phase 12025-11-15
RecruitingBioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast
Bioequivalence
Phase 12025-06-26
RecruitingStudy of SYH2062 Injection in Healthy Chinese Volunteers
Healthy Chinese Volunteers
Phase 12025-03-01
CompletedA Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterol
Hypercholesterolemia and Mixed Hyperlipidemia
Phase 22024-12-03
Not Yet RecruitingEfficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Post-operative Nausea and Vomiting (PONV)
Phase 32024-10-28
RecruitingA Bioequivalence Study of PP3M in Patients With Schizophrenia
Schizophrenia
N/A2024-10-09
CompletedA Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of S
Hyperlipemia
Phase 12024-01-08
Not Yet RecruitingA Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-R
High-risk (Secondary) Acute Myeloid Leukemia
Phase 32024-01-01
CompletedBioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia
Schizophrenia
N/A2023-12-18
UnknownA Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection
Acute Myeloid Leukemia
N/A2023-08-25
CompletedBioequivalence of Amphotericin B Liposome for Injection
Bioequivalence
Phase 12023-06-02
UnknownA Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergen
Hypertensive Emergency
Phase 32023-05-01
Not Yet RecruitingClinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine
Recurrent Metastatic Nasopharyngeal Carcinoma
Phase 32023-02-01
CompletedEfficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica
Neuromyelitis Optica Spectrum Disorder
Phase 22022-11-28
WithdrawnA Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Phase 22022-08-01
UnknownMitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
Relapsed or Refractory Multiple Myeloma
Phase 12021-10-20
UnknownBioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
Acute Myeloid Leukemia
N/A2020-09-04
CompletedA Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects
Bioequivalence
Phase 12020-06-04